Commercial point-of-care (POC) diagnostic tests for Group A Streptococcus, Streptococcus pneumoniae, and influenza virus have large potential diagnostic and financial impact. Many published reports on test performance, often funded by diagnostics companies, are prone to bias. The Standards for Reporting of Diagnostic Accuracy (STARD 2015) are a protocol to encourage accurate, transparent reporting. The Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool evaluates risk of bias and transportability of results. We used these tools to evaluate diagnostic test accuracy studies of POC studies for three respiratory pathogens. For the 96 studies analysed, compliance was <25% for 14/ 34 STARD 2015 standards, and 3/7 QUADAS-2 domains showed a high risk of bias. All reports lacked reporting of at least one criterion. These biases should be considered in the interpretation of study results.
assessment of diagnostic accuracy in systematic reviews was developed in 2003 and revised in 2011 [11, 12] . QUADAS evaluates study design and identifies potential sources of bias using seven different criteria, as well as threats to transportability of research results.
In 2009, Fontela et al. reported on the quality of 90 studies of POC tests for HIV, tuberculosis and malaria using QUADAS and STARD, and demonstrated moderate-to low-quality and poor reporting [13] . Common sources of bias were inadequate description of withdrawals and reference test execution, index test and reference test review bias, and under-reporting of uninterpretable results. Less than 25% of the included studies reported methods for calculation and estimates of test reproducibility, adverse effects, estimates of diagnostic accuracy between subgroups, distribution of severity of disease or other diagnoses in study participants, number of eligible patients who did not participate in the study, blinding of the test readers, description of the team executing the test and management of indeterminate, invalid or outlier results [13] In 2013, Jafari et al. investigated quality of studies of POC tests for Treponema pallidum (n = 33) using the same criteria, and demonstrated that five quality items remained unaddressed in 60% of papers, and clinical review bias, index test review bias, lack of reporting of uninterpretable results, reference test review bias and poor description of loss of patients were detected [14] . Wilczynski reviewed 240 studies from 2001 to 2005 and showed no improvement in completeness of reporting of following the initial publication of the STARD criteria [15] .
Our objective was to explore completeness of reporting and limitations of applicability among studies reporting POC diagnostic testing performance for Group A Streptococcus, S. pneumoniae, and influenza virus.
Methods

Article search strategy
A PubMed search was conducted using defined search criteria ('Group A Streptococcus [explode]', 'Pneumococcus [explode]', 'Influenza [explode]'). Studies were screened based on title and keywords and abstract by author MH. Inclusion and exclusion criteria were then applied to full-text studies by MH and PD.
Screening paper eligibility
The inclusion criteria were original studies published in English in peer-reviewed journals, which included clinical specimens from human subjects, were published between 2004 and 2015, and which reported diagnostic performance of commercial POC tests for either Group A Streptococcus, S. pneumoniae, or influenza A or B. Studies were excluded if they did not include original data, if tests could not be performed outside of a microbiological laboratory, if full text was not available or duplicate reports.
Data abstraction
The data extracted from included studies were year of publication, continent of origin, journal name, commercial name of index test performed, reference standard test performed, the number of patients ongoing each test, stated industry involvement as defined by donation of test kits or statement of involvement and stated conflict of interest as defined by explicit mention in the report.
Each article was analysed by two of three authors (MH, SB or CP). Discrepancies in interpretation were resolved by a fourth author (PD).
Methodological applicability and bias assessment using QUADAS-2
Methodological applicability and risk of bias were assessed using QUADAS-2 items, and determined to be of low, high or unclear risk of bias for each item in the tool. These assessments refer to the risk of incorrect study conclusions based on study methods. See Table 1 for an explanation of the QUADAS-2 assessment criteria [10] . The proportion of high or unclear risk of bias was compared between studies of each organism using Pearson χ 2 .
Reporting completeness assessment using STARD 2015
Reporting quality was assessed using the STARD 2015 checklist. Studies were evaluated based on the presence or absence of each criterion.
Statistical analysis was completed using SPSS (IBM® SPSS® Statistics Version 21, USA). All studies meeting inclusion criteria were analysed, and missing data were recorded as 'not reported'. STARD 2015 completeness scores were not combined into an overall score, as recommended by the original authors [10] , but reported as counts of criteria achieved. Pearson χ 2 was used to compare the proportion of criteria achieved. 
Ethics
Because patient information was not analysed, ethics approval was not required.
Results
Article search, screening and data abstraction
The PubMed search identified 34 174 potential studies (Fig. 1 ). Of these, 33 738 were excluded by removal of duplicate studies, review of title, keyword and abstract, and 340 studies were further excluded by full-text review. Overall, 96 studies were included, including antigen tests from throat swabs for Group A Streptococcus (n = 18), antigen tests from urine for S. pneumoniae (n = 19) and antigen and molecular tests for influenza (n = 60) ( Table 2) . Study characteristics are summarised in Table 3 . The median number of patients included per study for both index and reference tests was 303. Most studies were reported from Europe Methodological applicability and bias assessment using QUADAS-2 A summary of QUADAS-2 assessment can be found in Table 4 , and a comparison of bias by QUADAS-2 domain is found in Figure 2 .
Studies demonstrated a low risk of bias in three of the seven QUADAS-2 criteria, related to applicability, namely QUADAS2 (patient selection applicability), QUADAS4 (index test applicability) and QUADAS6 (reference test applicability). Studies demonstrated a high or unclear risk of bias in four of the seven QUADAS-2 criteria, related to risk of bias, namely QUADAS1 (patient selection risk of bias), QUADAS 3 (index test risk of 
Quality of reporting assessment using STARD 2015
A summary of STARD 2015 assessment by an organism can be found in Table 5 . The mean STARD compliance among all studies was 11/30 criteria (S.D. 4.3). Only two studies (2.1%) explicitly stated compliance with the STARD reporting guidelines. Mean STARD compliance between studies by an organism was similar (Group A Streptococcus 11.7 criteria, S. pneumoniae 13.4 criteria, influenza 10.0 criteria) (P = 0.38). Twenty criteria had low inclusion (<50% of studies included the criterion) (criteria 1, 2, 4, 5, 6, 9, 10, 12, 13, 14, 15, 16, 18, 20, 21, 22, 24, 25, 26, 28).
Discussion
We identified four QUADAS-2 criteria associated with a risk of bias that were at a high risk or unclear risk of bias among included studies. Studies performed better among criteria associated with applicability.
Patient selection risk of bias (QUADAS1)
To minimise the risk of bias in patient selection, a study should have appropriate methods of recruiting patients, such as either consecutive patients who present for care over time, or a random selection from a larger subset of patients. Included patients should be of heterogeneous composition, because exclusion of complex patients may overestimate test accuracy and compromise external validity of the study, whereas exclusion of healthy patients could underestimate test accuracy. Furthermore, case-control designs in which patients with obvious disease are selected as cases, and patients without obvious disease are selected as controls, could overestimate test accuracy through selection bias. We observed a large proportion of studies (42 studies, 43.8%) in which the assessment of risk of bias in patient selection was unclear, meaning that reports did not contain adequate information to reassure the reader that the risk of bias was low. Without this information, it is difficult to make inferences on the validity of the study.
Conduct or interpretation of index test (QUADAS3)
If index tests are interpreted with knowledge of the results of reference tests, index test interpretation may be biased towards overestimation of test accuracy. To prevent this bias, operators performing the test must perform the index test prior to the reference test, or at least must be adequately blinded to the reference test results. Reports must adequately describe the methods of blinding, such as performing the index test and reference test in two different laboratories, or relabelling and changing the order of specimens to protect the blind. A further cause of bias in conduct or interpretation of the index test is the timing in which the threshold of detection is determined. If the threshold of detection is selected based on analysing the completed study results, this may overestimate test accuracy. Threshold of detection should be defined prior to collecting data, and this must be stated in the report. We observed 46 studies (46.9%) in which information was not provided to allow the reader to assess that the index test was performed without bias (unclear risk of bias).
Reference test risk of bias (QUADAS5)
Bias may be introduced in the reference test if the reference test is unlikely to correctly classify the condition, or if the reference test Criterion 20 (any analysis of variability in diagnostic accuracy distinguishing pre-specified from exploratory) addresses test repeatability, which was generally not performed in the diagnostic studies we examined. Criterion 21 (intended sample size and how it was determined) reflects appropriate study planning to determine statistical power. Criterion 22 (flow of participants, using a diagram) accounts for patients lost to follow-up or excluded, which represent missing data. Criteria 24 and 25 (distribution of severity of disease in those with the target condition, distribution of alternate diagnoses in those without the target condition) address generalisability assessment. Criterion 26 (time interval and any clinical interventions between index test and reference standard) allows the reader to assess the risk that the patient's condition changed between index and reference test application. Criterion 29 (any adverse events from performing the index test or reference standard) was not reported by a single study. It is not generally suspected that the application of a diagnostic test should cause patient harm, however it is possible. Criterion 32 (registration number and name of registry) indicates transparency in design and reporting.
Many of the STARD 2015 reporting shortfalls previously noted [13, 14] are still lacking in this study, including lack of reporting of blinding for index and reference test execution, reporting of indeterminate and missing data, flow of participants and reporting of withdrawals, and distribution of severity of disease and alternative diagnoses [13, 14] . Therefore, despite updated criteria, there continues to be weak reporting of POC diagnostic studies for respiratory pathogens. This may be due to perceived lack of utility of reporting, or purposeful omission to enhance the perceived impact of the results. Continued weak adherence to STARD 2015 over included years from 2004 to 2015 enhances the findings by Wilczynski, which noted no change in quality, despite the publication of STARD [15] . This study reports on the studies of diagnostic accuracy for respiratory infections and indicates that there are many areas of reporting that fail to meet the outlined criteria. This has never been reported among tests for these pathogens. More stringent reporting requirements from journals, including reporting of the STARD 2015 criteria flowcharts in the methodology sections, may enhance the quality of published works.
Strengths of this study include reporting on POC tests in current use for common respiratory pathogens, and a comprehensive review of literature using broad search terms, which is believed to include all potential studies in the specified period at the time of 
